During the last session, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s traded shares were 2,927,792, with the beta value of the company hitting 2.65. At the end of the trading day, the stock’s price was $10.41, reflecting an intraday gain of 2.87% or $0.29. The 52-week high for the BCRX share is $14.24, that puts it down -36.79% from that peak though still a striking +81.65% gain since the share price plummeted to a 52-week low of $1.91. The company’s market capitalization is $1.85 Billion, and the average intraday trading volume over the past 10 days was 5.22 Million shares, and the average trade volume was 7.35 Million shares over the past three months.
BioCryst Pharmaceuticals, Inc. (BCRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2. BCRX has a Sell rating from none of the analyst(s) out of 11 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 9 recommend a Buy rating for it. None of the analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.27.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): Trading Information
BioCryst Pharmaceuticals, Inc. (BCRX) registered a 2.87% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.84% in intraday trading to $10.60 this Wednesday, Apr 07, hitting a weekly high. The stock’s 5-day price performance is 4.2%, and it has moved by -6.64% in 30 days. Based on these gigs, the overall price performance for the year is 39.73%. The short interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is 26.68 Million shares and it means that shorts have 3.63 day(s) to cover.
The consensus price target of analysts on Wall Street is $14.8, which implies an increase of 42.17% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $9 and $19 respectively. As a result, BCRX is trading at a discount of 82.52% off the target high and -13.54% off the low.
BioCryst Pharmaceuticals, Inc. (BCRX) projections and forecasts
Statistics show that BioCryst Pharmaceuticals, Inc. has underperformed its competitors in share price, compared to the industry in which it operates. BioCryst Pharmaceuticals, Inc. (BCRX) shares have gone up +185.6% during the last six months, with a year-to-date growth rate less than the industry average at -3.67% against 17.2%. Yet analysts are winding down their growth forecast for the fiscal year 2021. Revenue is predicted to decline -12.5% this quarter and then fall -4.2% in the quarter after that. In the rating firms’ projections, revenue will increase 245.2% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings fell an estimated -13.1%. While earnings are projected to return -16% in 2021, the next five years will return 19.9% per annum.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s Biggest Investors
BioCryst Pharmaceuticals, Inc. insiders own 0.93% of total outstanding shares while institutional holders control 69.8%, with the float percentage being 70.46%. Blackrock Inc. is the largest shareholder of the company, while 246 institutions own stock in it. As of Dec 30, 2020, the company held over 16.26 Million shares (or 9.16% of all shares), a total value of $121.14 Million in shares.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The next largest institutional holding, with 12.7 Million shares, is of Baker Brothers Advisors, LLC’s that is approximately 7.15% of outstanding shares. At the market price on Dec 30, 2020, these shares were valued at $94.58 Million.
Also, the Mutual Funds coming in first place with the largest holdings of BioCryst Pharmaceuticals, Inc. (BCRX) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Feb 27, 2021 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 7,957,249 shares. This amounts to just over 4.48 percent of the company’s overall shares, with a $85.78 Million market value. The same data shows that the other fund manager holds slightly less at 4.95 Million, or about 2.79% of the stock, which is worth about $36.87 Million.